nach oben

Journal of Neurology

Erschienen in:

08.01.2021 | Review

Rituximab for the treatment of multiple sclerosis: a review

verfasst von: Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, Simona Toscano, Maria Luca, Francesco Patti

Erschienen in: Journal of Neurology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

In the last decades, evidence suggesting the direct or indirect involvement of B cells on multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on the efficacy and safety of B-cell-depleting therapies from several studies has suggested the addition of these drugs as treatment options to the current armamentarium of disease modifying therapies (DMTs) for MS. Particularly, rituximab (RTX), a chimeric monoclonal antibody directed at CD20 positive B lymphocytes resulting in cell-mediated apoptosis, has been demonstrated to reduce inflammatory activity, incidence of relapses and new brain lesions on magnetic resonance imaging (MRI) in patients with relapsing–remitting MS (RRMS). Additional evidence also demonstrated that patients with progressive MS (PMS) may benefit from RTX, which also showed to be well tolerated, with acceptable safety risks and favorable cost-effectiveness profile.

Despite these encouraging results, RTX is currently approved for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, several forms of vasculitis and rheumatoid arthritis, while it can only be administered off-label for MS treatment. Between Northern European countries exist different rules for using not licensed drug for treating MS. The Sweden MS register reports a high rate (53.5%) of off-label RTX prescriptions in relation to other annually started DMTs to treat MS patients, while Danish and Norwegian neurologists have to use other anti-CD20 drugs, as ocrelizumab, in most of the cases.

In this paper, we review the pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile and cost effectiveness aspects of RTX for the treatment of MS. Particularly, with the approval of new anti-CD20 DMTs, the recent worldwide COVID-19 emergency and the possible increased risk of infection with this class of drugs, this review sheds light on the use of RTX as an alternative treatment option for MS management, while commenting the gaps of knowledge regarding this drug.

Segal BM (2019) The diversity of Encephalitogenic CD4+ T cells in multiple sclerosis and its animal models. J Clin Med 8(1):120. https://doi.org/10.3390/jcm8010120CrossRefPubMedCentral

Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545–558. https://doi.org/10.1038/nri3871CrossRefPubMed

Garg N, Smith TW (2015) An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 5(9):e00362. https://doi.org/10.1002/brb3.362CrossRefPubMedPubMedCentral

Wekerle H (2017) B cells in multiple sclerosis. Autoimmunity 50(1):57–60. https://doi.org/10.1080/08916934.2017.1281914CrossRefPubMed

Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8(11):613–623. https://doi.org/10.1038/nrneurol.2012.203CrossRefPubMed

Li R, Patterson KR, Bar-Or A (2018) Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19(7):696–707. https://doi.org/10.1038/s41590-018-0135-xCrossRefPubMed

Wanleenuwat P, Iwanowski P (2019) Role of B cells and antibodies in multiple sclerosis. Mult Scler Relat Disord 36:101416. https://doi.org/10.1016/j.msard.2019.101416CrossRefPubMed

Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A (2012) Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 246(1–2):85–95. https://doi.org/10.1016/j.jneuroim.2012.02.015CrossRefPubMed

Lassmann H (2018) Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol 9:3116. https://doi.org/10.3389/fimmu.2018.03116CrossRefPubMed

10.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Gronlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R (2018) Memory B cells activate brain-homing autoreactive CD4(+) T cells in multiple sclerosis. Cell 175(1):85–100. https://doi.org/10.1016/j.cell.2018.08.011CrossRefPubMedPubMedCentral

11.

Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, Reynolds R, O’Connor KC, Hafler DA (2011) Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 134(Pt 2):534–541. https://doi.org/10.1093/brain/awq350CrossRefPubMedPubMedCentral

12.

Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163(9):5133–5144PubMed

13.

Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH (2003) Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 171(5):2725–2733. https://doi.org/10.4049/jimmunol.171.5.2725CrossRefPubMed

14.

Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Investig 102(5):1045–1050. https://doi.org/10.1172/JCI3568CrossRefPubMedPubMedCentral

15.

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130(Pt 4):1089–1104. https://doi.org/10.1093/brain/awm038CrossRefPubMed

16.

Greenfield AL, Hauser SL (2018) B-cell therapy for multiple sclerosis: entering an era. Ann Neurol 83(1):13–26. https://doi.org/10.1002/ana.25119CrossRefPubMedPubMedCentral

17.

Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV (2012) The evidence for a role of B cells in multiple sclerosis. Neurology 78(11):823–832. https://doi.org/10.1212/WNL.0b013e318249f6f0CrossRefPubMedPubMedCentral

18.

Obermeier B, Lovato L, Mentele R, Bruck W, Forne I, Imhof A, Lottspeich F, Turk KW, Willis SN, Wekerle H, Hohlfeld R, Hafler DA, O’Connor KC, Dornmair K (2011) Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 233(1–2):245–248. https://doi.org/10.1016/j.jneuroim.2011.01.010CrossRefPubMedPubMedCentral

19.

Bankoti J, Apeltsin L, Hauser SL, Allen S, Albertolle ME, Witkowska HE, von Budingen HC (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75(2):266–276. https://doi.org/10.1002/ana.24088CrossRefPubMedPubMedCentral

20.

Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, Chan A, Stroet A, Olsson T, Willison H, Barnett SC, Meinl E, Linington C (2012) Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 135(Pt 6):1819–1833. https://doi.org/10.1093/brain/aws105CrossRefPubMedPubMedCentral

21.

Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579–582. https://doi.org/10.1016/S0140-6736(05)67102-4CrossRefPubMed

22.

Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349(2):139–145. https://doi.org/10.1056/NEJMoa022328CrossRefPubMed

23.

Rouwette M, Somers K, Govarts C, De Deyn PP, Hupperts R, Van Wijmeersch B, De Jong BA, Verbeek MM, Van Pesch V, Sindic C, Villar LM, Alvarez-Cermeno JC, Stinissen P, Somers V (2012) Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. J Neurochem 123(4):568–577. https://doi.org/10.1111/jnc.12005CrossRefPubMed

24.

Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14(2):164–174. https://doi.org/10.1111/j.1750-3639.2004.tb00049.xCrossRefPubMed

25.

Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6):3498–3506. https://doi.org/10.4049/jimmunol.176.6.3498CrossRefPubMed

26.

Aung LL, Balashov KE (2015) Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis. Mult Scler 21(9):1131–1138. https://doi.org/10.1177/1352458514560923CrossRefPubMed

27.

Krumbholz M, Meinl E (2014) B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 36(3):339–350. https://doi.org/10.1007/s00281-014-0424-xCrossRefPubMed

28.

Ireland SJ, Guzman AA, O’Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL (2014) The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol 71(11):1421–1428. https://doi.org/10.1001/jamaneurol.2014.1472CrossRefPubMedPubMedCentral

29.

Lossius A, Johansen JN, Torkildsen O, Vartdal F, Holmoy T (2012) Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Viruses 4(12):3701–3730. https://doi.org/10.3390/v4123701CrossRefPubMedPubMedCentral

30.

Endriz J, Ho PP, Steinman L (2017) Time correlation between mononucleosis and initial symptoms of MS. Neurol Neuroimmunol Neuroinflamm 4(3):e308. https://doi.org/10.1212/NXI.0000000000000308CrossRefPubMedPubMedCentral

31.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688. https://doi.org/10.1056/NEJMoa0706383CrossRefPubMed

32.

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K (2017) Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16:41–50. https://doi.org/10.1016/j.ebiom.2017.01.042CrossRefPubMedPubMedCentral

33.

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140–174. https://doi.org/10.1159/000082102CrossRefPubMed

34.

Lehmann-Horn K, Kinzel S, Weber MS (2017) Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function. Int J Mol Sci 18(10):2048. https://doi.org/10.3390/ijms18102048CrossRefPubMedCentral

35.

Ontaneda D, Hyland M, Cohen JA (2012) Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 63:389–404. https://doi.org/10.1146/annurev-med-042910-135833CrossRefPubMed

36.

Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, Islam-Jakobsson P, Malmestrom C, Axelsson M, Vagberg M, Sundstrom P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074–2081. https://doi.org/10.1212/WNL.0000000000003331CrossRefPubMedPubMedCentral

37.

Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460–471. https://doi.org/10.1002/ana.21867CrossRefPubMed

38.

D’Amico E, Zanghi A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M (2019) Effectiveness and safety of Rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord 27:324–326. https://doi.org/10.1016/j.msard.2018.09.041CrossRefPubMed

39.

Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G (2015) Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet 54(11):1107–1123. https://doi.org/10.1007/s40262-015-0296-9CrossRefPubMed

40.

Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45(7):792–801. https://doi.org/10.1177/0091270005277075CrossRefPubMed

41.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63(3):395–400. https://doi.org/10.1002/ana.21363CrossRefPubMed

42.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43. https://doi.org/10.1038/s41572-018-0041-4CrossRefPubMed

43.

Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F, van Berckel BN (2018) Cerebral rituximab uptake in multiple sclerosis: a (89)Zr-immunoPET pilot study. Mult Scler 24(4):543–545. https://doi.org/10.1177/1352458517704507CrossRefPubMed

44.

Petereit HF, Rubbert-Roth A (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 15(2):189–192. https://doi.org/10.1177/1352458508098268CrossRefPubMed

45.

Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3(3):166–179. https://doi.org/10.1002/acn3.293CrossRefPubMedPubMedCentral

46.

Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O’Brien J, Haqq C, Shuman M (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25(11):1350–1356. https://doi.org/10.1200/JCO.2006.09.7311CrossRefPubMed

47.

Schlachetzki F, Zhu C, Pardridge WM (2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81(1):203–206. https://doi.org/10.1046/j.1471-4159.2002.00840.xCrossRefPubMed

48.

Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101(2):466–468. https://doi.org/10.1182/blood-2002-06-1636CrossRefPubMed

49.

Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E (2016) The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult Scler Relat Disord 6:49–53. https://doi.org/10.1016/j.msard.2016.01.001CrossRefPubMed

50.

Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, Hopfner KP, Umana P, Niederfellner G (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5(1):22–33. https://doi.org/10.4161/mabs.22771CrossRefPubMedPubMedCentral

51.

Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, Coiffier B, Foa R, Wassner E, Burger HU, Brennan B, Mendila M (2010) Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21(9):1870–1876. https://doi.org/10.1093/annonc/mdq027CrossRefPubMed

52.

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 183(1):749–758. https://doi.org/10.4049/jimmunol.0900632CrossRefPubMed

53.

Robak T, Robak E (2011) New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25(1):13–25. https://doi.org/10.2165/11539590-000000000-00000CrossRefPubMed

54.

Maloney DG (2007) Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program 2007:226–232. https://doi.org/10.1182/asheducation-2007.1.226CrossRef

55.

Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 15(10):3266–3274. https://doi.org/10.1200/JCO.1997.15.10.3266CrossRefPubMed

56.

Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67(6):707–714. https://doi.org/10.1001/archneurol.2010.99CrossRefPubMedPubMedCentral

57.

Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67(4):452–461. https://doi.org/10.1002/ana.21939CrossRefPubMed

58.

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A, Canadian BciMST (2015) Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7(310):310ra166. https://doi.org/10.1126/scitranslmed.aab4176CrossRefPubMed

59.

Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E (2014) Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord 3(2):244–252. https://doi.org/10.1016/j.msard.2013.10.003CrossRefPubMed

60.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Budingen HC (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 193(2):580–586. https://doi.org/10.4049/jimmunol.1400118CrossRefPubMed

61.

Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13(1):25–36. https://doi.org/10.1038/nrneurol.2016.187CrossRefPubMed

62.

Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R (2019) The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res 14(3):373–386. https://doi.org/10.4103/1673-5374.245462CrossRefPubMedPubMedCentral

63.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74(23):1860–1867. https://doi.org/10.1212/WNL.0b013e3181e24373CrossRefPubMedPubMedCentral

64.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, Axelsson M, Malmestrom C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950–958. https://doi.org/10.1002/ana.24651CrossRefPubMed

65.

Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C (2018) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 13(5):e0197415. https://doi.org/10.1371/journal.pone.0197415CrossRefPubMedPubMedCentral

66.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75(3):320–327. https://doi.org/10.1001/jamaneurol.2017.4011CrossRefPubMedPubMedCentral

67.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL (2019) Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology 92(7):e723–e732. https://doi.org/10.1212/WNL.0000000000006916CrossRefPubMedPubMedCentral

68.

Brown BA, Torabi M (2011) Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf 34(2):117–123. https://doi.org/10.2165/11585960-000000000-00000CrossRefPubMed

69.

Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A (2018) Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler 24(9):1224–1233. https://doi.org/10.1177/1352458517720044CrossRefPubMed

70.

Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, Tian DS (2019) Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev 18(5):542–548. https://doi.org/10.1016/j.autrev.2019.03.011CrossRefPubMed

71.

Salvarani C, Brown RD Jr, Muratore F, Christianson TJH, Galli E, Pipitone N, Cassone G, Huston J III, Giannini C, Warrington K, Hunder GG (2019) Rituximab therapy for primary central nervous system vasculitis: a 6 patient experience and review of the literature. Autoimmun Rev 18(4):399–405. https://doi.org/10.1016/j.autrev.2018.12.002CrossRefPubMed

72.

Alvarez KNIS E, Sillau S, Vollmer T (2019) Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions—Abstract: P1402. ECTRIMS Online Library. Alvarez E. 09/13/19; 278602

73.

Joerger M (2012) Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 23(Suppl 10):x313-319. https://doi.org/10.1093/annonc/mds314CrossRefPubMed

74.

Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron PY, Hachulla E (2014) Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 33(6):799–805. https://doi.org/10.1007/s10067-014-2509-2CrossRefPubMedPubMedCentral

75.

Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, AutoImmunity and Rituximab registry and French Society of Rheumatology (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62(9):2625–2632. https://doi.org/10.1002/art.27555CrossRefPubMed

76.

Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47(2):187–198. https://doi.org/10.1053/j.seminhematol.2010.01.002CrossRefPubMed

77.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2019) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.3365CrossRefPubMedCentral

78.

Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896–3908. https://doi.org/10.1002/art.23059CrossRefPubMed

79.

Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A (2016) Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 263(2):322–326. https://doi.org/10.1007/s00415-015-7979-xCrossRefPubMed

80.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B (2019) Efficacy of rituximab in refractory RRMS. Mult Scler 25(6):828–836. https://doi.org/10.1177/1352458518772748CrossRefPubMed

81.

de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A (2016) Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 87(2):141–147. https://doi.org/10.1212/WNL.0000000000002832CrossRefPubMed

82.

Rommer PS, Dorner T, Freivogel K, Haas J, Kieseier BC, Kumpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK, GRAID Investigators (2016) Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a National Online Registry (GRAID). J Neuroimmune Pharmacol 11(1):1–8. https://doi.org/10.1007/s11481-015-9646-5CrossRefPubMed

83.

Alldredge B, Jordan A, Imitola J, Racke MK (2018) Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clin Neuropharmacol 41(2):56–59. https://doi.org/10.1097/WNF.0000000000000268CrossRefPubMed

84.

Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Konig R, Fiehn C, Burgwinkel P, Budde K, Sorensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T, GRAID Investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75. https://doi.org/10.1186/ar3337CrossRefPubMedPubMedCentral

85.

Hellgren J, Risedal A, Kallen K (2020) Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand 141(6):491–499. https://doi.org/10.1111/ane.13225CrossRefPubMed

86.

Mok CC (2013) Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 8:87–100. https://doi.org/10.2147/DDDT.S41645CrossRefPubMedPubMedCentral

87.

Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31(3):403–404. https://doi.org/10.1007/s00296-009-1202-2CrossRefPubMed

88.

Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, Shao JY, Lin TY, Jiang WQ, Zou DH, Hu LY, Wirian ML, Cai QQ (2015) Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer 34(5):225–234. https://doi.org/10.1186/s40880-015-0015-9CrossRefPubMed

89.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32(33):3736–3743. https://doi.org/10.1200/JCO.2014.56.7081CrossRefPubMed

90.

Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH (2015) Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61(2):703–711. https://doi.org/10.1002/hep.27609CrossRefPubMed

91.

(FDA) FaDA (2020) FDA Drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b. Accessed Nov 2020

92.

Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99(4):1486–1488. https://doi.org/10.1182/blood.v99.4.1486CrossRefPubMed

93.

Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Ikeda K, Tanimoto M, Hatake K (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87(4):393–397. https://doi.org/10.1007/s12185-008-0066-7CrossRefPubMed

94.

Sikkema T, Schuiling WJ, Hoogendoorn M (2013) Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep. https://doi.org/10.1136/bcr-2012-008142CrossRefPubMedPubMedCentral

95.

Oshima Y, Tanimoto T, Yuji K, Tojo A (2019) Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 25(8):1141–1149. https://doi.org/10.1177/1352458518786075CrossRefPubMed

96.

Narula S, LaRosa DF, Kamoun M, Dalmau J, Levinson AI (2007) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 98(5):483–489. https://doi.org/10.1016/S1081-1206(10)60764-8CrossRefPubMed

97.

Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924–2930. https://doi.org/10.1182/blood-2007-02-068999CrossRefPubMed

98.

Iacobaeus E, Burkill S, Bahmanyar S, Hakim R, Bystrom C, Fored M, Olsson T, Brundin L, Montgomery S (2018) The national incidence of PML in Sweden, 1988–2013. Neurology 90(6):e498–e506. https://doi.org/10.1212/WNL.0000000000004926CrossRefPubMedPubMedCentral

99.

Classifying PML risk with disease modifying therapies—FormSus. (2020). http://formsus.datasus.gov.br/novoimgarq/58543/13614899_312364.pdf

100.

Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R (2017) Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. J Neurovirol 23(5):742–749. https://doi.org/10.1007/s13365-017-0561-9CrossRefPubMed

101.

Kartau M, Sipila JO, Auvinen E, Palomaki M, Verkkoniemi-Ahola A (2019) Progressive Multifocal Leukoencephalopathy: current Insights. Degener Neurol Neuromuscul Dis 9:109–121. https://doi.org/10.2147/DNND.S203405CrossRefPubMedPubMedCentral

102.

Kridin K, Ahmed AR (2020) Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev 19(3):102466. https://doi.org/10.1016/j.autrev.2020.102466CrossRefPubMed

103.

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747–1756. https://doi.org/10.1084/jem.189.11.1747CrossRefPubMedPubMedCentral

104.

Ireland S, Monson N (2011) Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int 2011:423971. https://doi.org/10.1155/2011/423971CrossRefPubMedPubMedCentral

105.

Marcinno A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto A (2018) Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 5(6):e498. https://doi.org/10.1212/NXI.0000000000000498CrossRefPubMedPubMedCentral

106.

Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18. https://doi.org/10.4103/1735-1995.200275CrossRefPubMedPubMedCentral

107.

Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, Kahan A, Dieude P, Allanore Y (2018) Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum 48(2):149–154. https://doi.org/10.1016/j.semarthrit.2018.02.010CrossRefPubMed

108.

Isvy A, Meunier M, Gobeaux-Chenevier C, Maury E, Wipff J, Job-Deslandre C, Kahan A, Allanore Y (2012) Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 79(4):365–369. https://doi.org/10.1016/j.jbspin.2011.12.004CrossRefPubMed

109.

Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169. https://doi.org/10.1001/jamanetworkopen.2018.4169CrossRefPubMedPubMedCentral

110.

Rozman S, Sonc M, Novakovic BJ (2012) Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma 53(10):1945–1948. https://doi.org/10.3109/10428194.2012.679266CrossRefPubMed

111.

Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4(6):619–625. https://doi.org/10.1586/EHM.11.62CrossRefPubMed

112.

Rigal J, Ciron J, Lepine Z, Biotti D (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Mult Scler Relat Disord 41:102019. https://doi.org/10.1016/j.msard.2020.102019CrossRefPubMed

113.

Alcala C, Gascon F, Perez-Miralles F, Gil-Perotin S, Navarre A, Bosca I, Coret F, Casanova B (2018) Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol 265(7):1690–1697. https://doi.org/10.1007/s00415-018-8899-3CrossRefPubMed

114.

Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM (2018) Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res 2018:9084759. https://doi.org/10.1155/2018/9084759CrossRefPubMedPubMedCentral

115.

Wadstrom H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605–1612. https://doi.org/10.1001/jamainternmed.2017.4332CrossRefPubMedPubMedCentral

116.

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87(5):688–699. https://doi.org/10.1002/ana.25701CrossRefPubMed

117.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. https://doi.org/10.1056/NEJMoa0909905CrossRefPubMedPubMedCentral

118.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324. https://doi.org/10.1002/art.37754CrossRefPubMedPubMedCentral

119.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Juni P, Cattran DC, Investigators M (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36–46. https://doi.org/10.1056/NEJMoa1814427CrossRefPubMed

120.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220. https://doi.org/10.1056/NEJMoa0909169CrossRefPubMed

121.

Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100(2):432–441. https://doi.org/10.1210/jc.2014-2572CrossRefPubMed

122.

Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, Munoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juarez C, Verschuuren JJ, Illa I (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78(3):189–193. https://doi.org/10.1212/WNL.0b013e3182407982CrossRefPubMed

123.

Owczarczyk K, Hellmann M, Fliedner G, Rohrs T, Maizus K, Passon D, Hallek M, Rubbert A (2008) Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 67(11):1648–1649. https://doi.org/10.1136/ard.2007.087023CrossRefPubMed

124.

Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 37(5):917–927. https://doi.org/10.3899/jrheum.090442CrossRefPubMed

125.

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O (2019) Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 10:1990. https://doi.org/10.3389/fimmu.2019.01990CrossRefPubMedPubMedCentral

126.

Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456–473. https://doi.org/10.1016/j.ctrv.2005.05.007CrossRefPubMed

127.

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118(26):6769–6771. https://doi.org/10.1182/blood-2011-08-372649CrossRefPubMed

128.

Nazi I, Kelton JG, Larche M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM (2013) The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122(11):1946–1953. https://doi.org/10.1182/blood-2013-04-494096CrossRefPubMed

129.

Cho A, Bradley B, Kauffman R, Priyamvada L, Kovalenkov Y, Feldman R, Wrammert J (2017) Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight 2(12):e93222. https://doi.org/10.1172/jci.insight.93222CrossRefPubMedCentral

130.

Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124–133. https://doi.org/10.1196/annals.1313.014CrossRefPubMed

131.

Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET (2008) A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 126(3):282–290. https://doi.org/10.1016/j.clim.2007.11.012CrossRefPubMed

132.

Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK (2019) Vaccination in multiple sclerosis: friend or foe? Front Immunol 10:1883. https://doi.org/10.3389/fimmu.2019.01883CrossRefPubMedPubMedCentral

133.

(MabThera) EAoM-I-R (2020) https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf

134.

Administration FaD (2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf

135.

Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14(4):835–841. https://doi.org/10.1007/s13311-017-0557-4CrossRefPubMedPubMedCentral

136.

JR (2019) Rituximab for treatment of aggressive multiple sclerosis during pregnancy: a case study. Academy of American Neurology Annual Meeting, May 4–10, 2019; Philadelphia, PA Abstract P42–103

137.

LaHue S KK, Rutatangwa A, et al (2019) Minimal concentrations of rituximab in the breastmilk of women treated for multiple sclerosis. Academy of American Neurology Annual Meeting, May 4–10, 2019; Philadelphia, PA Abstract P42–097

138.

Matias-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA (2020) Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia 35(3):170–175. https://doi.org/10.1016/j.nrl.2020.03.001CrossRefPubMedPubMedCentral

139.

Salama S, Ahmed SF, Ibrahim Ismail I, Alroughani R (2020) Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clin Neurol Neurosurg 197:106203. https://doi.org/10.1016/j.clineuro.2020.106203CrossRefPubMedPubMedCentral

140.

Sokolowska M, Lukasik Z, Agache I, Akdis CA, Akdis D, Akdis M, Barcik W, Brough H, Eiwegger T, Eliaszewicz A, Eyerich S, Feleszko W, Gomez Casado C, Hoffmann-Sommergruber K, Janda J, Jimenez-Saiz R, Jutel M, Knol E, Kortekaas Krohn I, Kothari A, Makowska J, Moniuszko M, Morita H, O’Mahony L, Nadeau K, Ozdemir C, Pali-Scholl I, Palomares O, Papaleo F, Prunicki M, Schmidt-Weber CB, Sediva A, Schwarze J, Shamji MH, Tramper-Stranders G, van de Veen W, Untersmayr E (2020) Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. https://doi.org/10.1111/all.14462CrossRefPubMed

141.

Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 42:102120. https://doi.org/10.1016/j.msard.2020.102120CrossRefPubMedPubMedCentral

142.

Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374. https://doi.org/10.1038/s41577-020-0311-8CrossRefPubMed

143.

Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195. https://doi.org/10.1016/j.msard.2020.102195CrossRefPubMedPubMedCentral

144.

Maria Pia Sormani NDR, Irene Schiavetti Luca, Carmisciano CC, Lucia Moiola, Marta Radaelli, Paolo, Immovilli Marco Capobianco MT, Paola Zaratin, Gioacchino Tedeschi GC, Mario Alberto Battaglia, Francesco Patti MS, and the Musc-19 study group (2020) Disease modifying therapies and COVID-19 severity in multiple sclerosis. Lancet Neurol. Available at SSRN: https://doi.org/10.2139/ssrn.3631244

145.

Coles ALM, Giovannoni G, Anderson P, Dorsey-Campbell R, Qualie M, Vieira JJ (2020) ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf. Accessed Nov 2020

146.

Tepasse PR, Hafezi W, Lutz M, Kuhn J, Wilms C, Wiewrodt R, Sackarnd J, Keller M, Schmidt HH, Vollenberg R (2020) Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 190(2):185–188. https://doi.org/10.1111/bjh.16896CrossRefPubMed

147.

Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A (2020) Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler 26(10):1261–1264. https://doi.org/10.1177/1352458520943791CrossRefPubMedPubMedCentral

148.

Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149–161. https://doi.org/10.1111/cei.13495CrossRefPubMedPubMedCentral

149.

ClinicalTrials.gov (2020) A study to evaluate the effects of ocrelizumab on immune responses in participants with relapsing forms of multiple sclerosis. Accessed 22 Nov 2020

150.

Montero-Escribano P, Matias-Guiu J, Gomez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA (2020) Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid. Spain Mult Scler Relat Disord 42:102185. https://doi.org/10.1016/j.msard.2020.102185CrossRefPubMed

151.

D’Amico E, Chisari CG, Gitto L, Zanghi A, Toscano S, Patti F (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opin Pharmacother 20(11):1331–1340. https://doi.org/10.1080/14656566.2019.1615880CrossRefPubMed

152.

Du FH, Mills EA, Mao-Draayer Y (2017) Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights 8(1):12. https://doi.org/10.1007/s13317-017-0100-yCrossRefPubMedPubMedCentral

153.

Rognoni C, Bertolani A, Jommi C (2018) Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Glob Reg Health Technol Assess 5(1):1–11. https://doi.org/10.1177/228424031878428CrossRef

154.

Hartung DM (2017) Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics 14(4):1018–1026. https://doi.org/10.1007/s13311-017-0566-3CrossRefPubMedPubMedCentral

155.

Genenentech (2020) OCREVUS pricing and financial support https://www.ocrevus.com/patient/cost.html Accessed 20 Nov 2020

156.

Mullard A (2017) Bracing for the biosimilar wave. Nat Rev Drug Discov 16(3):152–154. https://doi.org/10.1038/nrd.2017.36CrossRefPubMed

157.

Simoens S (2011) Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 3:29–36. https://doi.org/10.2147/CEOR.S12494CrossRefPubMedPubMedCentral

158.

Montserrat E (2003) Rituximab in chronic lymphocytic leukemia. Semin Oncol 30(1S2):34–39. https://doi.org/10.1053/sonc.2003.50033CrossRefPubMed

159.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J (2019) Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. Eur J Neurol 26(8):1060–1067. https://doi.org/10.1111/ene.13936CrossRefPubMed

160.

Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54(8):2377–2386. https://doi.org/10.1002/art.22019CrossRefPubMed

161.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834–4840. https://doi.org/10.1182/blood-2008-10-186999CrossRefPubMedPubMedCentral

162.

Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68(9):1156–1164. https://doi.org/10.1001/archneurol.2011.103CrossRefPubMedPubMedCentral

163.

Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP (2012) Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler 18(3):377–378. https://doi.org/10.1177/1352458511418631CrossRefPubMed

164.

Shirani A, Okuda DT, Stuve O (2016) Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics 13(1):58–69. https://doi.org/10.1007/s13311-015-0409-zCrossRefPubMedPubMedCentral

165.

Studer V, Rossi S, Motta C, Buttari F, Centonze D (2014) Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. J Neuroimmunol 276(1–2):229–231. https://doi.org/10.1016/j.jneuroim.2014.08.617CrossRefPubMed

166.

Svenningsson A, Bergman J, Dring A, Vagberg M, Birgander R, Lindqvist T, Gilthorpe J, Bergenheim T (2015) Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm 2(2):e79. https://doi.org/10.1212/NXI.0000000000000079CrossRefPubMedPubMedCentral

167.

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A (2019) Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 266(1):57–67. https://doi.org/10.1007/s00415-018-9092-4CrossRefPubMed

168.

Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48(6):992–993. https://doi.org/10.1002/mus.24063CrossRefPubMedPubMedCentral

169.

Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE 13(1):e0190425. https://doi.org/10.1371/journal.pone.0190425CrossRefPubMedPubMedCentral

170.

Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412–1420. https://doi.org/10.1001/archneurol.2011.154CrossRefPubMed

171.

Jurczak W, Dlugosz-Danecka M (2020) Rituximab biosimilars in clinical practice. Leuk Lymphoma 61(7):1523–1524. https://doi.org/10.1080/10428194.2020.1788016CrossRefPubMed

172.

Initiative GaB (2020) EMA approval for rituximab biosimilar Truxima

173.

(EMA) EMA (2020) Rixathon https://www.ema.europa.eu/en/medicines/human/EPAR/rixathon. Accessed 10 Nov 2020

174.

Yoo DH, Suh CH, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY, Kwon TS, Park W (2017) A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 76(3):566–570. https://doi.org/10.1136/annrheumdis-2016-209540CrossRefPubMed

175.

Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M (2013) Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 27(5):495–507. https://doi.org/10.1007/s40259-013-0036-3CrossRefPubMedPubMedCentral

176.

Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J (2017) Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 4(8):e350–e361. https://doi.org/10.1016/S2352-3026(17)30106-0CrossRefPubMed

177.

Smolen JS, Cohen SB, Tony HP, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Zhu P, Shisha T (2017) A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 76(9):1598–1602. https://doi.org/10.1136/annrheumdis-2017-211281CrossRefPubMed

178.

Perez T, Rico A, Boutiere C, Maarouf A, Roudot M, Honore S, Pelletier J, Bertault-Peres P, Audoin B (2020) Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis. Mult Scler. https://doi.org/10.1177/1352458520912170CrossRefPubMed

179.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A (2019) Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 19(1):5–20. https://doi.org/10.1136/practneurol-2018-001899CrossRefPubMed

180.

Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165. https://doi.org/10.1016/S1474-4422(12)70310-1CrossRefPubMedPubMedCentral

181.

Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82(3):306–308. https://doi.org/10.1136/jnnp.2009.188912CrossRefPubMed

182.

Salvarani C, Brown RD Jr, Huston J 3rd, Morris JM, Hunder GG (2014) Treatment of primary CNS vasculitis with rituximab: case report. Neurology 82(14):1287–1288. https://doi.org/10.1212/WNL.0000000000000293CrossRefPubMed

183.

Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342–1348. https://doi.org/10.1001/jamaneurol.2016.1637CrossRefPubMed

184.

Palace J, Leite MI, Jacob A (2012) A practical guide to the treatment of neuromyelitis optica. Pract Neurol 12(4):209–214. https://doi.org/10.1136/practneurol-2012-000237CrossRefPubMed

185.

Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH, Yu C, Shi FD (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81(8):710–713. https://doi.org/10.1212/WNL.0b013e3182a1aac7CrossRefPubMedPubMedCentral

186.

Zhang M, Zhang C, Bai P, Xue H, Wang G (2017) Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg 117(3):695–702. https://doi.org/10.1007/s13760-017-0795-6CrossRefPubMed

187.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR, European Vasculitis S (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74(6):1178–1182. https://doi.org/10.1136/annrheumdis-2014-206404CrossRefPubMed

188.

National Institute for Health and Care Excellence technology appraisal guidance TA308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. https://www.nice.org.uk/guidance/ta308/chapter/1-Guidance. Accessed 16 Jun 2020

189.

Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262(5):1115–1119. https://doi.org/10.1007/s00415-014-7532-3CrossRefPubMed

190.

Tandan R, Hehir MK 2nd, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185–196. https://doi.org/10.1002/mus.25597CrossRefPubMed

191.

Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G (2020) SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann Neurol 87(6):794–797. https://doi.org/10.1002/ana.25770CrossRefPubMedPubMedCentral

Titel: Rituximab for the treatment of multiple sclerosis: a review
verfasst von: Clara Grazia Chisari
Eleonora Sgarlata
Sebastiano Arena
Simona Toscano
Maria Luca
Francesco Patti
Publikationsdatum: 08.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 1/2022
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10362-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

Parameters for subthalamic deep brain stimulation in patients with dystonia: a systematic review

Functional connectivity of hippocampus in temporal lobe epilepsy depends on hippocampal dominance: a systematic review of the literature

Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

Sex-specific differences in presentations and determinants of outcomes after endovascular thrombectomy for large vessel occlusion stroke

Correction to: Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review